Business
Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development
Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Markets (GEM). Under the agreement, GEM intends to provide up to NT$500 million in terms of strategic funding to support Senhwa's advancing pipeline, AI-enabled drug discovery initiatives, and global expansion strategy.
About this update from Senhwa Biosciences Inc
[{"type":"text","content":"TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Markets (GEM). Under the agreement, GEM intends to provide up to NT$500 million in terms of strategic funding to support Senhwa's advancing pipeline, AI-enabled drug discovery initiatives, and global expansion strategy.","length":516,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Senhwa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Senhwa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":213,"height":54,"url":"https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3NCDoiso4s2Ko03dxAmxgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNg--/https://media.zenfs.com/en/prnewswire.com/733155187d97c2430a91423c1587523b","width":213,"height":54}},"href":"https://mma.prnewswire.com/media/1933477/Senhwa_Logo_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This partnership highlights growing international investors' confidence in Senhwa's innovative R&D capabilities and its differentiated approach to integrating artificial intelligence into the development of its core assets. In addition to its ongoing focus on cancer immunotherapy, Senhwa has been actively building an AI-driven discovery platform. Through strategic collaboration with Y combinator backed AI Native company such as CellType, the Company is leveraging next-generation C2S (cell-to-sentence) technology to deepen mechanistic insights and systematically identify potential combination therapy in treating different types of cancers.","length":658,"tagName":"p"},{"type":"text","content":"AI-enabled validation has demonstrated that Senhwa's lead candidates possess promising immunomodulatory potential under specific tumor microenvironment conditions. These findings support the Company's "cold-to-hot tumor" strategy, positioning Senhwa to capture opportunities in the next wave of immuno-oncology (IO 2.0). Mechanism-driven, AI-assisted drug development is rapidly emerging as a key investment theme a...